Download - Acyclovir 2013.03.15 Lee, sang-hwi.

Transcript
Page 1: Acyclovir 2013.03.15 Lee, sang-hwi.

Acyclovir

2013.03.15Lee, sang-hwi

Page 2: Acyclovir 2013.03.15 Lee, sang-hwi.

1) Attachment ( 부착 )2) Fusion ( 융합 )3) Reverse transcription ( 역전사 )4) Integration ( 통합 )5) Transcrpition ( 전사 )6) Translation ( 유전자암호 해독 )7) Viral assembly ( 조립 ) 8) Budding and Maturation of HIV virion (HIV virion 의 돌출과 성숙 )• Retrovirus 는 lipid envelope 에 의해 둘러싸여 있는 protein capsid 안에 packaged 된 RNA genome 을 가지는 infectious particle 이다 . • lipid envelope 은 infection 과정 초기에 host cell의 membrane receptor 와 결합할 수 있는 receptor binding protein 을 포함하는 polypeptide chain 을 가진다 . • Retrovirus 는 유전물질로서 DNA 대신 RNA 와 DNA를 만드는 reverse transcriptase 을 가지고 있다 .

• Retrovirus 가 cell 에 감염되면 , cytoplasm 으로 re-verse transcriptase 와 RNA 를 주입된다 .

• 그 후 , chromosomal DNA 를 생성하고 host DNA에 삽입되어 복제를 시작한다

capsid

JAMA. 2002;287(13):1635-1637

Page 3: Acyclovir 2013.03.15 Lee, sang-hwi.

HIV Life Cycle and Anti-HIV Drug Design• Nucleoside reverse transcriptase inhibitors (NRTIs)• Nucleotide reverse transcriptase inhibitors (NtRTIs)• Non-nucleoside reverse transcriptase inhibitors

(NNRTIs)• Protease inhibitors (PIs)• Fusion inhibitors (FIs)• co-receptor inhibitors (CRIs)• Integrase inhibitors (INIs)

Page 4: Acyclovir 2013.03.15 Lee, sang-hwi.

Mechanism of action

AZV

• Aciclovir differs from previous nucleoside analogues in containing only a partial nucleoside structure : the sugar ring is replaced with an open-chain structure. • It is selectively converted into acyclo-guanosine monophosphate (acyclo-GMP) by viral thymidine kinase, which is far more effective (3000 times) in phosphorylation than cellular thymidine kinase. • Subsequently, the monophosphate form is further phosphorylated into the active triphosphate form, acyclo-guanosine triphosphate (acyclo-GTP), by cellular kinases. • Acyclo-GTP has approximately 100 times greater affinity for viral than cellular polymerase. • As a substrate, acyclo-GTP is incorporated into viral DNA, resulting in premature chain termination. • Although aciclovir resembles a nucleotide, it has no 3' end. • Therefore, after its incorporation into a growing DNA strand, no further nucleotides can be added to this strand. • It has also been shown that viral enzymes cannot remove acyclo-GTP from the chain, which results in inhibition of further activity of DNA polymerase. • Acyclo-GTP is fairly rapidly metabolised within the cell, possibly by cellular phosphatases. In sum, aciclovir can be considered a prodrug: it is administered in an inactive (or less active) form and is metabolised into a more active species after administration.

Page 5: Acyclovir 2013.03.15 Lee, sang-hwi.
Page 6: Acyclovir 2013.03.15 Lee, sang-hwi.

Mechanism of action of the NRTIsCytosine(C)

Deoxycytidine type

Page 7: Acyclovir 2013.03.15 Lee, sang-hwi.

NRTIs currently undergoing either phase II or phase IIIof clinical trials.

apricitabine racivir

amdoxovir elvucitabine

Cytosine(C)

Adenine(A)

Page 8: Acyclovir 2013.03.15 Lee, sang-hwi.

Structures of NtRTIs.

Page 9: Acyclovir 2013.03.15 Lee, sang-hwi.

Structures of anti-HIV NNRTIs.

FDA-approved Phase II or III

etravirine

nevirapinedelavirdine

특징 : 저항성 (resistance) 이 빠르다 . 다른 항레트로바이러스 약물과 병용 투여하도록 승인 화학변화 없이 직접억제

Page 10: Acyclovir 2013.03.15 Lee, sang-hwi.

Structures of anti-HIV PIs.

FDA-approved

saquinavi

ritonavir

darunavirindinavir

tipranavirfosamprenavir

nelfinavi

atazanavir

lopinavir/ritronaviramprenavir

Page 11: Acyclovir 2013.03.15 Lee, sang-hwi.
Page 12: Acyclovir 2013.03.15 Lee, sang-hwi.
Page 13: Acyclovir 2013.03.15 Lee, sang-hwi.
Page 14: Acyclovir 2013.03.15 Lee, sang-hwi.